Point-of-care diagnosis of pulmonary TB from urine samples
通过尿液样本即时诊断肺结核
基本信息
- 批准号:9166566
- 负责人:
- 金额:$ 27.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-03 至 2018-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAerosolsBacillus (bacterium)Base PairingBedside TestingsBiological AssayBloodCellsCessation of lifeChemistryChildClinicalClinical SensitivityCollectionComplexCoughingDNADetectionDevelopmentDevicesDiagnosisDiagnosticDiseaseEngineeringExperimental DesignsExposure toFoundationsGenbankGene TargetingGenesGenomeGenomicsGoalsGoldGrowthHIVHIV/TBHealth StatusHealthcareImmuneIndividualKidneyLengthLiteratureLow incomeLungMethodsMicroscopyMucous body substanceMycobacterium tuberculosisNucleic AcidsPatientsPerformancePopulationPreparationProcessPulmonary TuberculosisReactionReagentRecoveryReportingResearch DesignResourcesSamplingSensitivity and SpecificitySodium ChlorideSpecificitySputumStreamTestingTimeTreatment outcomeTuberculosisUrineWorkbaseburden of illnesscostdesigndisease diagnosisdisease transmissioneffective therapyimprovedlaboratory equipmentlaboratory facilitylow and middle-income countriespoint of caretreatment duration
项目摘要
M. tuberculosis (MTb) infects one-third of the world’s population, causes TB disease in 9 million
people per year, and is responsible for 1.7 million deaths annually. While effective treatments for
TB have been available for over 50 years, a major barrier to its control has remained the inability
to reliably diagnose disease in low-resource TB-endemic settings. Most clinical tests require an
adequate sample of sputum (mucus from the lungs) which may be difficult to obtain in patients
without a cough, in children, and in HIV-infected individuals. Urine offers an attractive method for
point-of-care TB diagnostics since it is abundant, simple to collect, and collection does not involve
exposure to infectious aerosols. Point-of-care TB diagnostics are urgently needed to decrease
disease transmission and improve treatment outcomes. The development of a PCR-based test of
TB from urine, and its development as a point-of-care test, could have enormous impact on TB
diagnostics.
Aim 1. Demonstrate the ability to diagnose pulmonary TB from patient urine. We will
evaluate the performance of detection for diagnosing pulmonary TB from urine of patients within
seven days of treatment initiation. We will calculate sensitivity in the 30 subjects known to have
pulmonary TB based on sputum analysis results, and calculate specificity in 50 healthy controls.
Aim 2. Enhance performance by expanding targets to additional regions of the TB genome.
Extensive analysis of the sensitivity and specificity of diagnostic targets in TB genomes is lacking.
We will analyze TB genomes in the NCBI GenBank to determine inclusiveness and specificity.
We will assess common targets in combination with other reported targets to identify a strong set
for high accuracy. As these assays are developed, we will re-test urine samples from Aim 1.
Aim 3. Demonstrate a point-of-care-compatible device based on quantitative engineering
of capture chemistry and conditions. We will quantify performance to allow informed
engineering to demonstrate a proof-of-principle device. The chosen demonstration will not be a
final device but will demonstrate a proof-of-principle that is aligned with the design goals: rapid
processing, self-contained shelf-stable reagents, no lab equipment, low-cost disposable
components, simple user steps, target recovery >80% from ~1 mL urine.
M.结核病(MTb)感染了世界三分之一的人口,导致900万人患结核病
每年造成170万人死亡。虽然有效的治疗方法
结核病已经存在了50多年,控制结核病的一个主要障碍仍然是
在资源匮乏的结核病流行环境中可靠地诊断疾病。大多数临床试验需要
可能难以从患者体内获得的足够的痰液样本(来自肺部的粘液)
在儿童和HIV感染者中,尿液提供了一种有吸引力的方法,
因为它丰富,易于收集,并且收集不涉及
接触传染性气溶胶迫切需要护理点结核病诊断,
疾病传播和改善治疗效果。建立了一种基于PCR的
尿液结核病及其作为即时检测的发展可能对结核病产生巨大影响
诊断
目标1.展示从病人尿液中诊断肺结核的能力。我们将
评价检测肺结核病人尿液的性能,
治疗开始7天。我们将计算30个已知有
肺结核的痰液分析结果的基础上,并计算特异性在50名健康对照。
目标2.通过将目标扩展到结核病基因组的其他区域来提高性能。
对结核病基因组中诊断靶点的敏感性和特异性缺乏广泛的分析。
我们将分析NCBI基因库中的TB基因组,以确定包容性和特异性。
我们将结合其他报告的目标评估共同目标,以确定一套强有力的目标
为了高精度。随着这些检测方法的开发,我们将重新检测目标1的尿液样本。
目标3。展示基于定量工程的床旁兼容设备
捕获化学和条件。我们将量化绩效,以便了解情况
工程来演示原理验证设备。选择的演示将不会是
最终器械,但将证明符合设计目标的原理验证:快速
处理,独立储存稳定的试剂,无需实验室设备,低成本一次性使用
组分,简单的用户步骤,目标回收率>80%,约1 mL尿液。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Barry Ryan Lutz其他文献
Barry Ryan Lutz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Barry Ryan Lutz', 18)}}的其他基金
Transrenal DNA for point-of-care diagnosis of TB
用于结核病即时诊断的经肾 DNA
- 批准号:
10285973 - 财政年份:2021
- 资助金额:
$ 27.04万 - 项目类别:
Transrenal DNA for point-of-care diagnosis of TB
用于结核病即时诊断的经肾 DNA
- 批准号:
10443886 - 财政年份:2021
- 资助金额:
$ 27.04万 - 项目类别:
Engineering a denaturant-resistant polymerase for direct nucleic acid diagnostics
设计用于直接核酸诊断的抗变性聚合酶
- 批准号:
10308721 - 财政年份:2020
- 资助金额:
$ 27.04万 - 项目类别:
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing
V-OLA:即时 HIV 病毒载量监测和耐药性测试
- 批准号:
10407553 - 财政年份:2019
- 资助金额:
$ 27.04万 - 项目类别:
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing
V-OLA:即时 HIV 病毒载量监测和耐药性测试
- 批准号:
10179314 - 财政年份:2019
- 资助金额:
$ 27.04万 - 项目类别:
V-OLA: point-of-care HIV viral load monitoring and drug resistance testing
V-OLA:即时 HIV 病毒载量监测和耐药性测试
- 批准号:
10655323 - 财政年份:2019
- 资助金额:
$ 27.04万 - 项目类别:
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring
HIV 特异性目标捕获和定量等温扩增,用于急性 HIV 诊断和治疗监测
- 批准号:
10471460 - 财政年份:2018
- 资助金额:
$ 27.04万 - 项目类别:
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring
HIV 特异性目标捕获和定量等温扩增,用于急性 HIV 诊断和治疗监测
- 批准号:
9975694 - 财政年份:2018
- 资助金额:
$ 27.04万 - 项目类别:
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoring
HIV 特异性目标捕获和定量等温扩增,用于急性 HIV 诊断和治疗监测
- 批准号:
10423662 - 财政年份:2018
- 资助金额:
$ 27.04万 - 项目类别:
相似海外基金
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
- 批准号:
10092043 - 财政年份:2024
- 资助金额:
$ 27.04万 - 项目类别:
EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
- 批准号:
2332007 - 财政年份:2024
- 资助金额:
$ 27.04万 - 项目类别:
Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000021/1 - 财政年份:2024
- 资助金额:
$ 27.04万 - 项目类别:
Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
- 批准号:
NE/Y000358/1 - 财政年份:2024
- 资助金额:
$ 27.04万 - 项目类别:
Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
- 批准号:
DP240100389 - 财政年份:2024
- 资助金额:
$ 27.04万 - 项目类别:
Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
- 批准号:
83001507 - 财政年份:2023
- 资助金额:
$ 27.04万 - 项目类别:
Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
- 批准号:
ST/X001091/1 - 财政年份:2023
- 资助金额:
$ 27.04万 - 项目类别:
Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
- 批准号:
2326096 - 财政年份:2023
- 资助金额:
$ 27.04万 - 项目类别:
Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
- 批准号:
10080253 - 财政年份:2023
- 资助金额:
$ 27.04万 - 项目类别:
Small Business Research Initiative